Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Drawing inferences from observational data with possible confounding Heart failure is increasing in prevalence and is a major cause of morbidity and mortality worldwide,1 with prevalence ranging from ...

SAN DIEGO -- Finerenone (Kerendia) yielded minimal renal benefit in patients with heart failure with mildly reduced or ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

Abiraterone use for prostate cancer can cause mineralocorticoid excess syndrome (MES; eg, hypertension and hypokalemia). Prednisone mitigates these effects; however, the optimal dose level is unclear.

Spironolactone inhibits the effects of aldosterone by binding to the mineralocorticoid receptor. Both insulin resistance and obesity have substantial effects on aldosterone action; 7,8 hence ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

An analysis of the FINEARTS-HF trial, which showed finerenone's benefits in heart failure outcomes, shows no significant ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Serum uric acid (SUA), a product of ...